# OnCo record second-cancers-after-anticancer-drug-treatment (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/second-cancers-after-anticancer-drug-treatment/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "second-cancers-after-anticancer-drug-treatment" ;
  schema:name "Second cancers caused by cancer drugs: monitoring on PARP inhibitors, BRAF inhibitors, lenalidomide, tamoxifen, radioligands and CAR T cells"@en ;
  schema:alternateName "second primary malignancy monitoring"@en, "therapy-related MDS and AML"@en, "secondary malignancies after CAR T"@en, "new primary cutaneous malignancies"@en, "skin checks on BRAF inhibitors"@en, "tamoxifen and womb cancer"@en, "MDS/AML on PARP inhibitors"@en, "SPM on lenalidomide"@en ;
  schema:description "Some cancer medicines can lead to a new, different cancer during treatment or years later. Each medicine's label says what to watch for: regular blood counts on olaparib and niraparib, skin checks on vemurafenib, encorafenib and ripretinib, prompt tests for unexpected vaginal bleeding on tamoxifen, and lifelong follow-up after CAR T cells. Your own team's plan comes first."@en ;
  schema:url <https://onco.cc/protocols/second-cancers-after-anticancer-drug-treatment/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  onco:related <https://onco.cc/protocols/survivorship-care-plan-and-treatment-summary/>, <https://onco.cc/protocols/long-term-follow-up-after-childhood-cancer/>, <https://onco.cc/protocols/breast-screening-after-chest-radiotherapy-at-a-young-age/>, <https://onco.cc/protocols/sun-protection-during-and-after-cancer-treatment/>, <https://onco.cc/protocols/breast-cancer-follow-up-after-treatment/>, <https://onco.cc/protocols/bone-marrow-aspirate-and-trephine-biopsy/>, <https://onco.cc/cancers/aml-secondary/>, <https://onco.cc/technologies/skin-cancer-screening/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/ripretinib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/drugs/idecabtagene-vicleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/brexucabtagene-autoleucel/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/keratoacanthoma/>, <https://onco.cc/terms/squamous-cell-carcinoma/>, <https://onco.cc/terms/cytogenetics/>, <https://onco.cc/terms/bone-marrow/> .
